US Bancorp
KNTE

US Bancorp’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

US Bancorp’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-113
Closed -$689 – 4224
2022
Q4 		$689 Sell
113
-1,949
-95% -$15.9K ﹤0.01% 3968
2022
Q3 		$25K Buy
2,062
+83
+4% +$1.09K ﹤0.01% 2929
2022
Q2 		$25K Buy
1,979
+979
+98% +$9.11K ﹤0.01% 2939
2022
Q1 		$11K Buy
+1,000
New +$11K ﹤0.01% 3357
2021
Q4 		– Sell
-100
Closed -$2K – 4261
2021
Q3 		$2K Buy
100
+50
+100% +$1.09K ﹤0.01% 3941
2021
Q2 		$1K Buy
+50
New +$1.27K ﹤0.01% 3964

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

US Bancorp's KNTE Position: Q1 2023 in Review

US Bancorp sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q1 2023, closing a stake of 113 shares — an estimated $689 sold.

US Bancorp first reported a position in KNTE in Q2 2021 and held it in 6 quarters. The position peaked at $25K in Q3 2022. 71 funds tracked by Wall St. Rank hold KNTE as of Q1 2023.

  • US Bancorp reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • US Bancorp sold 113 Kinnate Biopharma Inc. Common Stock shares in Q1 2023, an estimated $689.
  • US Bancorp first reported a position in Kinnate Biopharma Inc. Common Stock in Q2 2021 and held it in 6 quarters.
  • US Bancorp's Kinnate Biopharma Inc. Common Stock position peaked at $25K in Q3 2022.
  • 71 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q1 2023.

Based on US Bancorp's 13F filing for Q1 2023, filed 9 May 2023.